TICKERNERD
Menu
CGENCGENHealthcare · Biotechnology

CGEN Stock Forecast: Compugen Ltd. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$2.03
+1.00% on the day

The 5 Wall Street analysts covering Compugen Ltd. hold a median 12-month price target of $4 — +97.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 75 of 100 as at 3 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$190.4M
Ticker Nerd rank
75/ 100
Median analyst target
$4.00
Analysts covering
5
Revenue$2.6M+107.0% y/y
Operating income−$8.8M
Net income−$7.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.0%
1M
−12.1%
YTD
+32.7%
1Y
+26.1%
From 52W high
−34.5%
From 52W low
+38.1%
$1.47
$3.10
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CGEN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Compugen Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Nov 2026
75/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
99
Quality
72
Momentum
68
Size
67
Revisions
64
Value
63
Issuance
49
Volatility
39
Accruals
21

Growth (99): Sales and profits are climbing, and climbing faster than before.

Accruals (21): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CGEN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CGEN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00$6.00Jan 26Apr 26Jul 26Oct 26CGENHigh $6.00Median $4.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $4.00Median $4.00High $6.00

The green dot is the last close — the median target sits +97.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Oct 2026HC Wainwright & Co.ReiteratesBuy$4.00
21 May 2026Leerink PartnersMaintainsOutperform—
7 Apr 2026Lake StreetInitiatesBuy—
7 Jan 2026HC Wainwright & Co.InitiatesBuy—
21 May 2024Truist SecuritiesMaintainsBuy—
8 Mar 2024Truist SecuritiesMaintainsBuy—
19 Dec 2023StifelMaintainsBuy—
23 Aug 2023Truist SecuritiesReiteratesBuy—
7 Aug 2023EF HuttonReiteratesBuy—
6 June 2023EF HuttonReiteratesBuy—
26 May 2023EF HuttonReiteratesBuy—
24 May 2023EF HuttonReiteratesBuy—
16 May 2023OppenheimerMaintainsOutperform—
28 Feb 2023OppenheimerReiteratesOutperform—
8 Feb 2023JefferiesDowngradeUnderperform—
5 Jan 2023EF HuttonInitiatesBuy—
15 Nov 2022OppenheimerMaintainsOutperform—
23 Aug 2022Truist SecuritiesMaintainsBuy—
8 Aug 2022JMP SecuritiesMaintainsMarket Outperform—
8 Aug 2022OppenheimerMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

CGEN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CGEN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, Compugen Ltd. returned +26.1% against +14.8% for the S&P 500, dividends included.

CGEN vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180Jan 26Apr 26Jul 26Oct 26CGENS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CGEN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Compugen Ltd. (CGEN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
5.3×

Cheaper than 65% of US stocks

Price / sales
2.6×

Cheaper than 44% of US stocks

Price / book
2.1×

Cheaper than 40% of US stocks

EV / EBITDA
2.2×

Cheaper than 56% of US stocks

Growth & margins
Revenue growth (YoY)
107.0%

Higher than 93% of US stocks

Earnings growth (YoY)
107.0%

Higher than 84% of US stocks

Gross margin
−3.5%

Higher than 4% of US stocks

Operating margin
−339.6%

Higher than 9% of US stocks

Net margin
47.6%

Higher than 95% of US stocks

Returns & dividend
Return on equity
50.6%

Higher than 93% of US stocks

Return on assets
15.5%

Higher than 97% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Compugen Ltd. (CGEN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Compugen Ltd. has a market value of $190.4M and an enterprise value of $68.1M.

  • Revenue in the twelve months to 30 June 2026: $74.0M. The latest quarter grew 107.0% year on year.

  • Net income over the same four quarters: $35.2M, a 47.6% net margin.

  • Diluted earnings per share, trailing twelve months: $0.38.

  • Shares outstanding: 94.7M.

  • Trailing P/E: 5.3×; forward P/E: −5.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Compugen Ltd. employs 75 people — $987K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Nov 2026

Data provided by Twelve Data

Peers

CGEN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CGENCompugen Ltd.$190.4M75
RNACCartesian Therapeutics, Inc.$187.8M33
DTILPrecision BioSciences, Inc.$192.4M71
PRQRProQR Therapeutics NV$193.3M46
BBOTBridgebio Oncology Therapeutics, Inc.$186.0M6
RNAAtrium Therapeutics, Inc.$194.2M5
UPBUpstream Bio, Inc.$185.7M26

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Compugen Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CGEN news & analysis

Compugen to Participate in November Investor Conferences

PRNewsWire · 3 Nov 2026neutral

Compugen said management will participate in two November 2026 investor conferences: the Stifel Healthcare Conference in New York and the Jefferies Global Healthcare Conference in London. Its Stifel schedule includes a fireside chat and one-on-one meetings; Jefferies participation is scheduled for one-on-one meetings.

Why it matters — The conferences provide CGEN watchers with information on when management is scheduled to meet with investors and participate in a fireside chat.

Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor Targets

MarketBeat · 5 Oct 2026positive

Compugen outlined the clinical rationale for its COM701 antibody in platinum-sensitive ovarian cancer and announced an expansion of its AI-powered discovery platform into tumor-associated antigen research during a company update event.

Why it matters — This provides CGEN watchers with updates on the company's ovarian cancer clinical program and a broadening of its AI drug-discovery capabilities into a new target area.

Compugen Ltd. (CGEN) Discusses COM701 in Ovarian Cancer, MAIA Trial Preview, and UNIGEN Platform Advancements Transcript

Seeking Alpha · 5 Oct 2026neutral

Compugen Ltd. discussed its COM701 candidate in ovarian cancer, provided a preview of the MAIA trial, and detailed advancements in its UNIGEN platform during a company transcript covered by Seeking Alpha.

Why it matters — CGEN watchers would gain insight into the company's clinical pipeline and platform developments that could shape its future.

FAQ

Frequently asked questions about CGEN stock

What is the CGEN stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Compugen Ltd. have a median 12-month price target of $4, with estimates ranging from $4 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CGEN stock a buy right now?

Of the 5 analysts covering Compugen Ltd., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Compugen Ltd. 75 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CGEN?

As at 3 Nov 2026, Compugen Ltd. ranks 75 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).

Will CGEN stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +97.0% from the last close, and Ticker Nerd's factor model ranks Compugen Ltd. 75 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CGEN stock forecast for 2030?

No analyst covering Compugen Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CGEN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $6 over the next 12 months.

How has CGEN stock performed over the past year?

Compugen Ltd. returned +26.1% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Compugen Ltd. do?

Compugen Ltd. is a clinical-stage therapeutic discovery and development company focused on cancer immunotherapy and autoimmune diseases.

What is the latest news on CGEN?

The most recent item we track (PRNewsWire, 3 Nov 2026): "Compugen to Participate in November Investor Conferences". Compugen said management will participate in two November 2026 investor conferences: the Stifel Healthcare Conference in New York and the Jefferies Global Healthcare Conference in London. Its Stifel schedule includes a fireside chat and one-on-one meetings; Jefferies participation is scheduled for one-on-one meetings.

Company

About Compugen Ltd.

Compugen Ltd. is a clinical-stage therapeutic discovery and development company focused on cancer immunotherapy and autoimmune diseases. Compugen Ltd. uses its AI- and machine learning-powered Unigen platform to identify novel drug targets, validate biological pathways, and advance therapeutic and diagnostic biomarker candidates. Its current work centers on developing antibodies and other biologic product candidates for oncology and immune-related conditions, with programs designed to address unmet needs in solid tumors and inflammatory diseases. The company operates across Israel, the United States, and Europe, supporting research, development, and commercial collaboration activities. Headquartered in Holon, Israel, Compugen Ltd. plays a role in the biotechnology market as a platform-driven company that combines computational discovery with experimental development to build differentiated drug candidates.

CEO Dr. Eran Ophir Ph.D. · 75 employees · Israel · https://cgen.com